Madrigal Pharmaceuticals (MDGL) Assets (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Assets of $1.2 billion for Q2 2026, up 22.58% year-over-year from $1.0 billion in Q2 2025, and up 1.41% quarter-over-quarter from $1.2 billion in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Assets (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Assets for 17 consecutive years, with $1.2 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Assets rose 22.58% year-over-year to $1.2 billion; the TTM figure through Jun 2026 stood at $1.2 billion (up 22.58% YoY), while the FY2025 annual figure was $1.3 billion, up 20.85% from the prior year.
- Assets improved to $1.2 billion in Q2 2026 per MDGL's latest filing, from $1.2 billion in the prior quarter.
- Across five years, Assets topped out at $1.4 billion in Q3 2025 and bottomed at $158.6 million in Q3 2022.
- Historically, Assets has averaged $771.0 million across 5 years, with a median of $1.0 billion in 2025.
- Annual changes were most pronounced in 2022 — Assets tumbled 47.93% — and 2024, when it jumped 351.02%.
- Madrigal Pharmaceuticals' Assets stood at $362.6 million in 2022, then soared by 76.67% to $640.5 million in 2023, then soared by 62.71% to $1.0 billion in 2024, then gained by 20.85% to $1.3 billion in 2025, then declined by 1.19% to $1.2 billion in 2026.
- Business Quant data shows MDGL's Assets at $1.2 billion in Q2 2026, $1.2 billion in Q1 2026, and $1.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | 1.24 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.24 Bn |
| Mar 31, 2026 | 1.23 Bn |
| Dec 31, 2025 | 1.26 Bn |
| Sep 30, 2025 | 1.36 Bn |
| Jun 30, 2025 | 1.02 Bn |
| Mar 31, 2025 | 996.63 Mn |
| Dec 31, 2024 | 1.04 Bn |
| Sep 30, 2024 | 1.07 Bn |
| Jun 30, 2024 | 1.10 Bn |
| Mar 31, 2024 | 1.08 Bn |
| Dec 31, 2023 | 640.55 Mn |
| Sep 30, 2023 | 237.96 Mn |
| Jun 30, 2023 | 302.46 Mn |
| Mar 31, 2023 | 332.45 Mn |
| Dec 31, 2022 | 362.57 Mn |
| Sep 30, 2022 | 158.64 Mn |
| Jun 30, 2022 | 216.39 Mn |
| Mar 31, 2022 | 222.66 Mn |
| Dec 31, 2021 | 273.33 Mn |
| Sep 30, 2021 | 304.70 Mn |